Document

SC 13G 1 schedule13g-ajkazimi2020.htm SC 13G Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________________________________

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 11)*

__________________________________________

Cumberland Pharmaceuticals Inc.

_______________________________________

(Name of Issuer)

Common Stock

__________________________________________

(Title of Class of Securities)

230770109

__________________________________________

(CUSIP Number)

December 31, 2020

__________________________________________

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

o Rule 13d-1(c)

x Rule 13d-1(d)


*			The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



CUSIP No. 230770109



1	NAMES OF REPORTING PERSONS. A.J. Kazimi
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) Not applicable (a) o (b) o
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		5	SOLE VOTING POWER 5,793,069
		6	SHARED VOTING POWER None
		7	SOLE DISPOSITIVE POWER 5,793,069
		8	SHARED DISPOSITIVE POWER None
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,793,069
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable o
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 37.65%
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN

Page 2 of 5 pages

Item 1.


			(a)			Name of Issuer


						Cumberland Pharmaceuticals Inc.


			(b)			Address of Issuer's Principal Executive Offices


						2525 West End Avenue, Suite 950, Nashville, TN 37203

Item 2.


			(a)			Name of Person Filing


						A.J. Kazimi


			(b)			Address of Principal Business Office or, if none, Residence


						2525 West End Avenue, Suite 950, Nashville, TN 37203


			(c)			Citizenship


						United States


			(d)			Title of Class of Securities


						Common Stock


			(e)			CUSIP Number


						230770109

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable

Item 4. Ownership.


			(a)			Amount beneficially owned:


						5,793,069


			(b)			Percent of class:


						37.65%

Page 3 of 5 pages


			(c)			Number of shares as to which the person has:


			(i)			Sole power to vote or to direct the vote


						5,793,069


			(ii)			Shared power to vote or to direct the vote


						None.


			(iii)			Sole power to dispose or to direct the disposition of


						5,793,069


			(iv)			Shared power to dispose or to direct the disposition of


						None.

Item 5. Ownership of Five Percent or Less of a Class

Not applicable

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9. Notice of Dissolution of Group

Not applicable

Item 10. Certification

Not applicable

Page 4 of 5 pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


			February 12, 2021
			Date

			/s/ A.J. Kazimi*
			Signature

			A.J. Kazimi, Chief Executive Officer
			Name/Title

* By: /s/ Michael Bonner, as attorney-in-fact, pursuant to a Power of Attorney dated April 26, 2016 and filed with the SEC on May 27, 2016.

Page 5 of 5 pages